Chul Soo Ha

Medicine and Dentistry

1. Radiation Therapy 100%
2. Chemotherapy 53%
3. Diseases 43%
4. Hodgkin's Lymphoma 39%
5. Prognostic Factor 24%
6. Overall Survival 22%
7. Non-Hodgkin Lymphoma 21%
8. Doxorubicin 19%
9. Vincristine 18%
10. Follicular Lymphoma 17%
11. Neoplasm 17%
12. Prednisone 16%
13. Multimodality Cancer Therapy 15%
14. International Prognostic Index 12%
15. Malignant Neoplasm 11%
16. Survival Rate 11%
17. Cyclophosphamide 11%
18. CHOP 10%
19. MALT Lymphoma 10%
20. Progression Free Survival 10%
21. Pediatrics 9%
22. Recurrence Free Survival 9%
23. Lung 9%
24. Lymphocyte 9%
25. Prostate Cancer 9%
26. Recurrent Disease 8%
27. Median Follow Up 8%
28. Aggressive Lymphoma 8%
29. Plasmacytoma 8%
30. Pelvis 7%
31. Involved-Field Radiotherapy 6%
32. Polymerase Chain Reaction 6%
33. Whole Body Radiation 6%
34. Tomotherapy 6%
35. Treatment Modality 6%
36. Intensity Modulated Radiation Therapy 6%
37. Vinblastine 6%
38. Cancer 6%
39. Disease Free Survival 5%
40. Induction Chemotherapy 5%
41. Multiple Myeloma 5%
42. Lymphoblastic Lymphoma 5%
43. Large-Cell Lymphoma 5%
44. Multivariate Analysis 5%
45. Long-Term Outcome 5%
46. T Cell 5%
47. Immunoblastic Lymphoma 5%
48. Disease Exacerbation 5%
49. Diffuse Large B-Cell Lymphoma 5%
50. Single-Photon Emission Computed Tomography 5%